JP2021530453A5 - - Google Patents
Info
- Publication number
- JP2021530453A5 JP2021530453A5 JP2020571855A JP2020571855A JP2021530453A5 JP 2021530453 A5 JP2021530453 A5 JP 2021530453A5 JP 2020571855 A JP2020571855 A JP 2020571855A JP 2020571855 A JP2020571855 A JP 2020571855A JP 2021530453 A5 JP2021530453 A5 JP 2021530453A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- pharmaceutically acceptable
- pharmaceutical composition
- stereoisomer
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023126807A JP2023145694A (ja) | 2018-06-29 | 2023-08-03 | 免疫調節化合物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692176P | 2018-06-29 | 2018-06-29 | |
| US62/692,176 | 2018-06-29 | ||
| PCT/US2019/039509 WO2020006233A1 (en) | 2018-06-29 | 2019-06-27 | Immunomodulatory compounds |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126807A Division JP2023145694A (ja) | 2018-06-29 | 2023-08-03 | 免疫調節化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021530453A JP2021530453A (ja) | 2021-11-11 |
| JP2021530453A5 true JP2021530453A5 (cg-RX-API-DMAC7.html) | 2022-07-05 |
| JP7328263B2 JP7328263B2 (ja) | 2023-08-16 |
Family
ID=68987232
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020571855A Active JP7328263B2 (ja) | 2018-06-29 | 2019-06-27 | 免疫調節化合物 |
| JP2023126807A Pending JP2023145694A (ja) | 2018-06-29 | 2023-08-03 | 免疫調節化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023126807A Pending JP2023145694A (ja) | 2018-06-29 | 2023-08-03 | 免疫調節化合物 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US12234220B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3814330A4 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7328263B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102834593B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113166100A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019293235B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3102212A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020006233A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN118108706A (zh) * | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| CA3102212A1 (en) * | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
| KR102947433B1 (ko) | 2019-04-12 | 2026-04-06 | 씨4 테라퓨틱스, 인코포레이티드 | 이카로스 및 아이올로스의 트리시클릭 분해제 |
| JP7852923B2 (ja) * | 2019-11-27 | 2026-04-28 | キャプター セラピューティクス エス.エー. | セレブロンに結合するピペリジン-2,6-ジオン誘導体、及びその使用方法 |
| PH12022551482A1 (en) | 2019-12-18 | 2023-11-29 | Novartis Ag | 3-(5-methoxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof |
| WO2022255889A1 (en) * | 2021-06-01 | 2022-12-08 | Captor Therapeutics S.A. | Compounds which bind to cereblon, and use thereof |
| WO2022254362A1 (en) | 2021-06-03 | 2022-12-08 | Novartis Ag | 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof |
| JP2025531869A (ja) | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | CK1αおよびDUAL CK1α/GSPT1分解化合物 |
| CN116655595A (zh) * | 2023-06-05 | 2023-08-29 | 中国人民解放军军事科学院军事医学研究院 | 2,6-哌啶二酮衍生物及其制备和用途 |
| AU2024344247A1 (en) | 2023-09-19 | 2026-05-07 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5698579A (en) * | 1993-07-02 | 1997-12-16 | Celgene Corporation | Cyclic amides |
| US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
| WO2008007979A1 (en) * | 2006-07-12 | 2008-01-17 | Auckland Uniservices Limited | (2,6-dioxo-3-piperinyl)amidobenzoic immunomodulatory and anti-cancer derivatives |
| US9345705B2 (en) | 2011-09-15 | 2016-05-24 | Merck Sharp & Dohme Corp. | Compositions and methods for treating cancer |
| CN109153644B (zh) * | 2016-03-16 | 2022-10-21 | H·李·莫菲特癌症中心研究有限公司 | 用以增强效应t细胞功能的针对cereblon的小分子 |
| CN121974842A (zh) * | 2016-05-10 | 2026-05-05 | C4医药公司 | 用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体 |
| IL319363A (en) * | 2017-01-31 | 2025-05-01 | Arvinas Operations Inc | Cervalon ligands and bifunctional compounds containing them |
| CN118108706A (zh) | 2017-09-04 | 2024-05-31 | C4医药公司 | 戊二酰亚胺 |
| US11512080B2 (en) | 2018-01-12 | 2022-11-29 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| CA3102212A1 (en) * | 2018-06-29 | 2020-01-02 | Dana-Farber Cancer Institute, Inc. | Immunomodulatory compounds |
-
2019
- 2019-06-27 CA CA3102212A patent/CA3102212A1/en active Pending
- 2019-06-27 EP EP19826640.5A patent/EP3814330A4/en active Pending
- 2019-06-27 WO PCT/US2019/039509 patent/WO2020006233A1/en not_active Ceased
- 2019-06-27 KR KR1020217002635A patent/KR102834593B1/ko active Active
- 2019-06-27 US US17/255,738 patent/US12234220B2/en active Active
- 2019-06-27 AU AU2019293235A patent/AU2019293235B2/en active Active
- 2019-06-27 CN CN201980056905.1A patent/CN113166100A/zh active Pending
- 2019-06-27 JP JP2020571855A patent/JP7328263B2/ja active Active
-
2023
- 2023-08-03 JP JP2023126807A patent/JP2023145694A/ja active Pending